Andreas D. Hartkopf

ORCID: 0000-0003-1227-1118 · 6 papers in corpus
review 2024
Journal of clinical medicine ·doi:10.3390/jcm13247530

Background/Objectives: Endometriosis and urogenital malformation with uterus didelphys and renal agenesis might occur concomitantly, and the question arises whether both entities are associated with each other. Methods: A literature search …

2023
·doi:10.1055/a-2097-5680

2019 wurden in deutschen Krankenhäusern insgesamt 748492 Geburten registriert, 3 Jahre zuvor wurden knapp 133000 Patient*innen mit Mammakarzinom vollstationär behandelt 1 2. Ein Uterus myomatosus kann ab dem Alter von 50 Jahren bei mehr als…

observational 2023
The journal of pathology. Clinical research ·doi:10.1002/cjp2.311

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carci…

review 2023
Geburtshilfe und Frauenheilkunde ·doi:10.1055/a-2073-1887

In patients with existing ovarian function, there are some special aspects to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-negative (HR pos./HER2 neg.) breast cancer. Treatment options include ta…

observational 2020
British journal of cancer ·doi:10.1038/s41416-020-0900-0

BACKGROUND: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarke…

observational 2018
The journal of pathology. Clinical research ·doi:10.1002/cjp2.109

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemi…